Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study. (PubMed, Int J Clin Oncol) - Sep 20, 2026 - "Tarlatamab demonstrated numerically longer OS and DOR, and higher ORR versus amrubicin in Japanese patients with SCLC, with fewer high-grade treatment-related adverse events. These results in Japanese patients support those of the global population."
Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|
|
Hiroaki Akamatsu; Hiroki Izumi; Hiroshi Kagamu; Hiroshi Tanaka; Hiroshi Yokouchi; Jihyun Park; Kadoaki Ohashi; Kazumi Nishino; Kazushige Wakuda; Koichi Azuma; Makoto Nishio; Miyako Satouchi; Shuang Huang; Shuji Murakami; Shunichi Sugawara; Taichi Miyawaki; Takayasu Kurata; Takayuki Takahama; Tatsuya Yoshida; Upen Patil
|